Bond Screener
Sucampo Pharmaceuticals
LEI 549300YPLK5FSJFMAH24
Liquidated
Organization name
Sucampo Pharmaceuticals Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Credit Ratings
in foreign currency
Public debt
-
New to Cbonds? · Take a 90-second tour of the platform.
Discover what you can do with Cbonds
Everything you need for fixed income research and monitoring.
- 00:23 Coverage
- 00:40 Bond screener
- 00:54 Parameters
- 01:10 Watchlist, Mobile app
- 01:15 Excel Add-in
Trading Schedule Issuer map
Quotes
/
/
/
pcs.
pcs.
pcs.
- «
- 1
- ...
- {{ quotes.page - 2 }}
- {{ quotes.page - 1 }}
- {{ quotes.page }}
- {{ quotes.page + 1 }}
- {{ quotes.page + 2 }}
- ...
- {{ quotesLastPage }}
- »
Quotes provided by information providers are indicative in nature
Profile
|
A subsidiary of Mallinckrodt plc closed its acquisition of the company on February 13, 2018. Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally.Sucampo Pharmaceuticals, Inc. was founded in 1996 is headquartered in Rockville, Maryland.
|
General information
-
Organization nameSucampo Pharmaceuticals Inc.
-
Organization statusLiquidated
-
Address805 King Farm Boulevard Rockville, USA, 20850
Stocks
General information
-
Organization nameSucampo Pharmaceuticals Inc.
-
Organization statusLiquidated
-
Address805 King Farm Boulevard Rockville, USA, 20850
Codes
-
LEI549300YPLK5FSJFMAH24
-
SIC2834 PHARMACEUTICAL PREPARATIONS
-
NACE*** ***
-
NAICS*** ***
-
CIK0001182197
